{"category":{"kind":"industry","slug":"biotech","name":"BioTech","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"pr","added_at":"2026-09-02T12:02:47.147Z","updated_at":"2026-09-02T12:02:47.147Z","example":false,"profile_url":"/industries/biotech","is_stub":true,"member_count":265,"member_counts":{"accelerator":11,"company":254}},"members":[{"listing_type":"company","name":"Virelion Biotech","slug":"virelion-biotech","tagline":"Engineering The Heart","description":"Virelion Biotech is an early-stage biotechnology venture building computational and experimental infrastructure for cardiac regeneration, cardiovascular phenotyping, translational research, and biological decision support. Its modular research stack connects cardiac data and evidence, experimental design, biological measurement, machine learning, benchmarking, evaluation, simulation, provenance, and interoperability.","url":"https://virelionbiotech.netlify.app/","is_stealth":false,"normalized_domain":"virelionbiotech.netlify.app","normalized_url_key":"virelionbiotech.netlify.app","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"X / Twitter","url":"https://x.com/VirelionBiotech","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/virelion/","platform":"linkedin"},{"label":"Instagram","url":"https://www.instagram.com/virelionbiotech/","platform":"instagram"}],"entry_points":[{"kind":"homepage","url":"https://virelionbiotech.netlify.app/","audience":"any","primary":false,"listed_by":"owner","derived_from":"url","on_listing_domain":true},{"kind":"github","url":"https://github.com/Virelion-Biotech","audience":"any","primary":false,"listed_by":"owner","derived_from":"github","on_listing_domain":false}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://virelionbiotech.netlify.app/","audience":"any","primary":false,"listed_by":"owner","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"person_slug":"syed-umer-hannan-3fblh9ry0wa0i","name":"Syed Umer Hannan","role":"CEO","bio":null,"location":null,"image_url":null,"image_asset_id":null,"links":[]}],"media":{"logo_asset_id":"afde59ab-e89b-41a3-a020-ef010a06040e","cover_asset_id":"84b21595-2a73-4f76-a4bb-4f91cb6ab830","screenshot_asset_ids":[]},"categories":["Biotech","Life Sciences","AI","Deep Tech","Healthcare","Biomedical Engineering","Research","Regenerative Medicine"],"stage":"pre-seed","founded_year":2024,"location":"United States","pricing":"Free","twitter":null,"github":"https://github.com/Virelion-Biotech","linkedin":null,"contact_email":"virelion85@gmail.com","added_at":"2026-09-23T15:12:56.531Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"verified","claimed_by_agent_id":null,"claimed_via_claim_id":"cfd71606-484a-4cc6-9e3b-36d9903241bc","claimed_at":"2026-09-23T15:17:45.470Z","updated_at":"2026-09-23T15:17:45.470Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biomedical-engineering","name":"Biomedical Engineering","note":null,"profile_url":"/industries/biomedical-engineering"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-tech","name":"Deep Tech","note":null,"profile_url":"/industries/deep-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"regenerative-medicine","name":"Regenerative Medicine","note":null,"profile_url":"/industries/regenerative-medicine"},{"kind":"industry","slug":"research","name":"Research","note":null,"profile_url":"/industries/research"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-23T15:12:56.531Z","updated_at":"2026-09-23T15:12:56.531Z"}},{"listing_type":"company","name":"Alethio Therapeutics","slug":"alethio-therapeutics","tagline":"Disease-modifying biologics for myeloproliferative neoplasms","description":"Alethio Therapeutics (formerly Alethiomics) is a University of Oxford spin-out developing disease-modifying therapies for myeloproliferative neoplasms (MPNs). Its ARTEMIS discovery engine combines patient-derived multi-omics, machine learning, and organoid models; lead programme ATX-011 is a first-in-class monoclonal antibody targeting G6B on the mutant MPN clone. On November 5, 2026 the company announced an oversubscribed $90 million (£67 million) Series A to advance ATX-011 into clinical studies.","url":"https://alethiotherapeutics.com/","is_stealth":false,"normalized_domain":"alethiotherapeutics.com","normalized_url_key":"alethiotherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"$90M Series A (company news, Nov 5, 2026)","url":"https://alethiotherapeutics.com/alethio-therapeutics-raises-90-million-67-million-in-oversubscribed-series-a-financing-to-advance-a-new-generation-of-therapies-for-myeloproliferative-neoplasms/","platform":"news"}],"entry_points":[{"kind":"homepage","url":"https://alethiotherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://alethiotherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Therapeutics","Oncology","Drug Discovery"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/alethiomics","contact_email":null,"added_at":"2026-11-06T07:29:31.652Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-06T07:29:42.588Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-06T07:29:31.652Z","updated_at":"2026-11-06T07:29:31.652Z"}},{"listing_type":"company","name":"Potential Sciences","slug":"potential-sciences","tagline":"Physics-based AI models for computational chemistry and drug discovery","description":"Potential Sciences is a UK startup building physics-based computational chemistry models to accelerate molecular design and drug discovery. In November 2026 the UK Sovereign AI fund and other backers including Nauta Capital supported the company in a multi-million-dollar raise, with Stripe CEO Patrick Collison among reported supporters.","url":"https://potentialsciences.com/","is_stealth":false,"normalized_domain":"potentialsciences.com","normalized_url_key":"potentialsciences.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://potentialsciences.com/og.jpg","links":[{"label":"X","url":"https://x.com/potentialsci_","platform":"x"},{"label":"GitHub","url":"https://github.com/potential-sciences","platform":"github"},{"label":"Tech.eu funding coverage","url":"https://tech.eu/2026/11/05/uk-sovereign-ai-fund-and-stripe-ceo-back-potential-sciences-in-multi-million-dollar-raise/","platform":"news"}],"entry_points":[{"kind":"homepage","url":"https://potentialsciences.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://potentialsciences.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"a927ef23-f556-4920-ba6c-62f36208912b"},"categories":["AI","Drug Discovery","Computational Chemistry","Biotech"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/potential-sciences","contact_email":null,"added_at":"2026-11-06T04:31:15.579Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-06T04:31:37.608Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"computational-chemistry","name":"Computational Chemistry","note":null,"profile_url":"/industries/computational-chemistry"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-06T04:31:15.579Z","updated_at":"2026-11-06T04:31:15.579Z"}},{"listing_type":"company","name":"Thryv Therapeutics","slug":"thryv-therapeutics","tagline":"Precision medicines for cardiac arrhythmias and heart failure","description":"Thryv Therapeutics develops precision medicines for heart rhythm disorders and heart failure. In November 2026 it announced a $30 million Series B financing to launch the ASPIRE-HF study of THRV-1268 in patients with heart failure, and reported that its Wave II Long QT Syndrome efficacy cohort was fully enrolled.","url":"https://thryvtrx.com/","is_stealth":false,"normalized_domain":"thryvtrx.com","normalized_url_key":"thryvtrx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static1.squarespace.com/static/5e6153344479f8487b130068/t/697a5910be8c5f43d9989030/1769625872459/Thryv+favicon.png","links":[{"label":"X","url":"https://x.com/ThryvTrx","platform":"x"},{"label":"Series B announcement","url":"https://thryvtrx.com/news/series-b-aspire-hf","platform":"news"}],"entry_points":[{"kind":"homepage","url":"https://thryvtrx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://thryvtrx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"ff8cae8c-39d8-4db3-a373-c29591756d48"},"categories":["Biotech","Cardiology","Therapeutics"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/thryv-therapeutics-inc","contact_email":null,"added_at":"2026-11-06T04:28:33.190Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-06T04:28:55.172Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cardiology","name":"Cardiology","note":null,"profile_url":"/industries/cardiology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-06T04:28:33.190Z","updated_at":"2026-11-06T04:28:33.190Z"}},{"listing_type":"company","name":"ArrayPatch","slug":"arraypatch","tagline":"Polymer-free dissolving microneedle patches for drug delivery","description":"ArrayPatch is a Cork, Ireland biotechnology company developing DerMap, a dissolving microneedle patch made entirely from the drug itself for pain-free intradermal delivery. Its pipeline includes GLP-DerMap for obesity and type 2 diabetes medicines, Skin Cancer DerMap, and ITZ-DerMap for onychomycosis. In November 2026 it completed an oversubscribed €3.2 million seed financing to advance next-generation microneedle therapeutics.","url":"https://array-patch.com/","is_stealth":false,"normalized_domain":"array-patch.com","normalized_url_key":"array-patch.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://array-patch.com/wp-content/uploads/2024/05/Heading2-ezgif.com-png-to-webp-converter.webp","links":[{"label":"€3.2M seed (GlobeNewswire, Nov 2026)","url":"https://www.globenewswire.com/news-release/2026/11/05/3396093/0/en/arraypatch-completes-oversubscribed-3-2-million-seed-financing-to-advance-next-generation-microneedle-therapeutics.html","platform":"news"}],"entry_points":[{"kind":"homepage","url":"https://array-patch.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://array-patch.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"4ee82e79-7fdf-4f77-995a-90d4f2dc419e"},"categories":["Biotech","Drug Delivery","Digital Health","Therapeutics"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/arraypatch-ltd","contact_email":null,"added_at":"2026-11-06T04:26:34.163Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-06T04:26:56.055Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"digital-health","name":"Digital Health","note":null,"profile_url":"/industries/digital-health"},{"kind":"industry","slug":"drug-delivery","name":"Drug Delivery","note":null,"profile_url":"/industries/drug-delivery"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-06T04:26:34.163Z","updated_at":"2026-11-06T04:26:34.163Z"}},{"listing_type":"company","name":"Nova Anchora","slug":"nova-anchora","tagline":"Topical collagen VII therapy for dystrophic epidermolysis bullosa","description":"Nova Anchora is a Boston biotechnology company developing NvA-021, an investigational topical gel containing recombinant human collagen VII for dystrophic epidermolysis bullosa (DEB). The program holds an exclusive license from Stanford University, has received FDA pre-IND feedback, and carries Orphan Drug and Rare Pediatric Disease designations. In November 2026 the company announced a $23 million equity financing led by Viking Global Investors, with participation from DEBRA Research, EB Research Partnership, the EB Medical Research Foundation, and Cure EB, to advance manufacturing, IND-enabling work, and an initial clinical proof-of-concept study.","url":"https://www.novaanchora.com/","is_stealth":false,"normalized_domain":"novaanchora.com","normalized_url_key":"novaanchora.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static1.squarespace.com/static/689e495683e997531f578f1c/t/689e4bc24cd88470f3f57175/1755204546179/Printable+resolution+file.jpg?format=1500w","links":[{"label":"$23M financing (GlobeNewswire, Nov 2026)","url":"https://www.globenewswire.com/news-release/2026/11/05/3396351/0/en/nova-anchora-announces-23-million-financing-to-advance-topical-collagen-vii-therapy-for-dystrophic-epidermolysis-bullosa.html","platform":"news"}],"entry_points":[{"kind":"homepage","url":"https://www.novaanchora.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.novaanchora.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"48dc7052-b437-4b9b-8e85-cbb65a7ea646"},"categories":["Biotech","Rare Disease","Dermatology","Therapeutics"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/nova-anchora","contact_email":null,"added_at":"2026-11-06T04:25:05.669Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-06T04:25:26.783Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"dermatology","name":"Dermatology","note":null,"profile_url":"/industries/dermatology"},{"kind":"industry","slug":"rare-disease","name":"Rare Disease","note":null,"profile_url":"/industries/rare-disease"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-06T04:25:05.669Z","updated_at":"2026-11-06T04:25:05.669Z"}},{"listing_type":"company","name":"Actithera","slug":"actithera","tagline":"Next-generation radioligand therapies designed for prolonged tumor retention","description":"Actithera is a radiopharmaceutical biotechnology company developing radioligand therapies that link radioactive isotopes to designed molecules for targeted cancer treatment. The company aims for prolonged tumor retention while limiting exposure to healthy tissue, with programs advancing toward clinical development. Actithera has offices in Cambridge, Massachusetts, and Norway.","url":"https://actithera.com/","is_stealth":false,"normalized_domain":"actithera.com","normalized_url_key":"actithera.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://listedstartups.com/media/0a12718f-0385-4ece-853b-00084aab49fd","links":[],"entry_points":[{"kind":"homepage","url":"https://actithera.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://actithera.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"625238e0-c1da-4351-866b-7a4394ea7cc4"},"categories":["Biotech","Health","Therapeutics","Deep Tech"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/actithera","contact_email":null,"added_at":"2026-11-06T01:19:41.901Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-06T01:24:25.756Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-tech","name":"Deep Tech","note":null,"profile_url":"/industries/deep-tech"},{"kind":"industry","slug":"health","name":"Health","note":null,"profile_url":"/industries/health"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-06T01:19:41.901Z","updated_at":"2026-11-06T01:19:41.901Z"}},{"listing_type":"company","name":"bit.bio","slug":"bit-bio","tagline":"Human cell models reprogrammed from stem cells at scale","description":"bit.bio is a Cambridge, UK synthetic biology company whose opti-ox technology reprograms human stem cells into specific cell types precisely, consistently and at scale. Its ioCells human cell models are used in drug discovery, disease research, functional genomics and toxicology. In November 2026 bit.bio announced a $25 million Series D, with participation from existing investor M&G Investments, to expand its cell-model portfolio.","url":"https://www.bit.bio/","is_stealth":false,"normalized_domain":"bit.bio","normalized_url_key":"bit.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.bit.bio/hs-fs/hubfs/Logos/bit.bio/bitbio-logotype-no_tagline-color-positive-RGB.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.bit.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.bit.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"438c4ead-431d-4c7e-8cca-ec03e48597ae"},"categories":["Biotech","Synthetic Biology","Life Sciences"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/bitbioltd","contact_email":null,"added_at":"2026-11-05T13:24:00.900Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-05T13:25:25.773Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-05T13:24:00.900Z","updated_at":"2026-11-05T13:24:00.900Z"}},{"listing_type":"company","name":"Biograil","slug":"biograil","tagline":"Swallowable capsule device for oral delivery of injectable drugs","description":"Biograil is a Copenhagen-based biotech company developing pharmaceutical products based on its BIONDD device, which sits inside a standard-size capsule and delivers therapeutics that would otherwise be injected into the stomach mucosal wall for systemic absorption. In November 2026 it announced a €20 million financing round backed by Verve Ventures and Megatrend Invest, with HTGF participating, to prepare BIONDD for phase 1 clinical testing.","url":"https://biograil.com/","is_stealth":false,"normalized_domain":"biograil.com","normalized_url_key":"biograil.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://biograil.com/wp-content/uploads/2020/02/biograil-logo-pos.png","links":[],"entry_points":[{"kind":"homepage","url":"https://biograil.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://biograil.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"c7799fa7-b009-453a-af55-13c0cf0d94e4"},"categories":["Biotech","Healthcare","Medical Devices"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-11-05T13:23:57.297Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-05T13:25:09.430Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-devices","name":"Medical Devices","note":null,"profile_url":"/industries/medical-devices"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-05T13:23:57.297Z","updated_at":"2026-11-05T13:23:57.297Z"}},{"listing_type":"company","name":"Venomics AI","slug":"venomics-ai","tagline":"AI-driven drug discovery from animal venoms","description":"Venomics AI is a Bengaluru biotechnology company spun out of the Indian Institute of Science (IISc) that combines venom biology, molecular sequencing, AI and laboratory screening to discover venom-derived therapeutic leads. It is building the Venom Atlas, a molecular dataset linking venom-derived molecules to experimentally measured activity, and uses AI to prioritise candidates that are then validated in its wet lab. Co-founded by Kartik Sunagar and Vinay Prabhu, it announced a $2.7 million pre-seed round co-led by Speciale Invest and South Park Commons in November 2026.","url":"https://venomics.ai/","is_stealth":false,"normalized_domain":"venomics.ai","normalized_url_key":"venomics.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://venomics.ai/assets/logos/apple-touch-icon.png","links":[],"entry_points":[{"kind":"homepage","url":"https://venomics.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://venomics.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2b4d96b3-c06e-441b-8878-6fe2e122fa5e"},"categories":["Biotech","AI","Healthcare"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-11-05T13:23:43.104Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-05T13:24:44.036Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-05T13:23:43.104Z","updated_at":"2026-11-05T13:23:43.104Z"}},{"listing_type":"company","name":"Intology","slug":"intology","tagline":"Building Locus, an autonomous AI R&D system that runs and iterates on experiments","description":"Intology is automating R&D. Its system Locus formulates experiment ideas, executes several experiments in parallel on purpose-built infrastructure, and samples new experiments based on evaluation feedback. Intology has published results applying Locus to language model post-training, ML research engineering and, in November 2026, molecular discovery tasks (molecular property prediction, small-molecule potency prediction with Boltz-2, and antibody design workflows), where it reports outperforming expert baselines and generalist coding agents under matched compute. Performance figures are company-reported.","url":"https://intology.ai/","is_stealth":false,"normalized_domain":"intology.ai","normalized_url_key":"intology.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://intology.ai/apple-touch-icon.png","links":[{"label":"X","url":"https://x.com/intology","platform":"x"},{"label":"Automating AI R&D for Molecular Discovery (Nov 2026)","url":"https://intology.ai/blog/automating-ai-rd-for-molecular-discovery","platform":"blog"}],"entry_points":[{"kind":"homepage","url":"https://intology.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://intology.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"833b3ce2-0ae9-4f37-9c0e-dfbe11bc65cc"},"categories":["AI","Research","Biotech","Machine Learning"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-11-03T22:23:32.849Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-03T22:23:32.849Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"machine-learning","name":"Machine Learning","note":null,"profile_url":"/industries/machine-learning"},{"kind":"industry","slug":"research","name":"Research","note":null,"profile_url":"/industries/research"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-03T22:23:32.849Z","updated_at":"2026-11-03T22:23:32.849Z"}},{"listing_type":"company","name":"Specific Biologics","slug":"specific-biologics","tagline":"Toronto biotech developing Dualase genome editors as in vivo therapies, starting with C9ORF72 ALS","description":"Specific Biologics is a Toronto-based biotechnology company developing in vivo genome-editing medicines built on its Dualase editors. Dualase uses a two-site mechanism, pairing an engineered Cas domain with an I-TevI nuclease domain, to enable precise removal, repair and insertion of DNA sequences, with an initial focus on removing expanded DNA repeats. Its pipeline spans CNS, lung and liver indications, delivered by single AAV or encapsulated all-RNA formats. In November 2026 it announced an oversubscribed $35 million Series A led by Hatteras Venture Partners to take its Dualase candidate into an adaptive Phase I/II trial for C9ORF72-associated ALS.","url":"https://www.specificbiologics.com/","is_stealth":false,"normalized_domain":"specificbiologics.com","normalized_url_key":"specificbiologics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static.wixstatic.com/media/d0f7a9_acfb3ad5a6f94f91b217d095941c3487~mv2.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.specificbiologics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.specificbiologics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"f12f6525-511a-4d8c-9c84-e62bd77de12e"},"categories":["Biotech","Gene Editing","Therapeutics"],"stage":null,"founded_year":null,"location":"Toronto, Ontario, Canada","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/specific-biologics","contact_email":null,"added_at":"2026-11-03T13:19:24.032Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-03T13:23:00.623Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-editing","name":"Gene Editing","note":null,"profile_url":"/industries/gene-editing"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-03T13:19:24.032Z","updated_at":"2026-11-03T13:19:24.032Z"}},{"listing_type":"company","name":"Vitroscope","slug":"vitroscope","tagline":"Perfusion platforms that keep living human tissue and organoids viable for real-time drug discovery research","description":"Vitroscope is a Norwegian biotech company based in Trondheim that develops perfusion platforms for studying immune activity, treatment responses and disease mechanisms in living human tissue. Its benchtop system, vitro.alive, combines programmable perfusion, real-time control of oxygen, pH and temperature, and live-cell imaging in a well-plate footprint with six independent channels, and works with standard inverted microscopes and a browser-based experiment interface. A higher-throughput platform, vitro.scale, is planned for launch in 2028. In November 2026 Vitroscope raised $7 million: a $5 million seed round co-led by Cerberus Ventures and YZR Capital plus $2 million in non-dilutive funding from the Research Council of Norway.","url":"https://www.vitroscope.com/","is_stealth":false,"normalized_domain":"vitroscope.com","normalized_url_key":"vitroscope.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.vitroscope.com/vitroscope_logo.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.vitroscope.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.vitroscope.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"bc361c22-ac1b-4523-a8e0-079b4e5ce1b5"},"categories":["Biotech","Life Sciences","Drug Discovery"],"stage":null,"founded_year":null,"location":"Trondheim, Norway","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/vitroscope/","contact_email":null,"added_at":"2026-11-03T13:19:14.180Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-03T13:22:45.809Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-03T13:19:14.180Z","updated_at":"2026-11-03T13:19:14.180Z"}},{"listing_type":"company","name":"imphatec","slug":"imphatec","tagline":"Customisable-dose drug implants aiming for a pill-free future for chronic conditions","description":"imphatec Ltd is a British synthetic biology pharmaceutical company developing a subcutaneous implant platform that releases medication long-term with no patient input, with a dose that can be personalised to each patient. Its first focus is hypothyroidism, and the platform is designed to be applied to other established medications for chronic conditions. The implants have progressed through pre-clinical stages. Co-founded by Dr Hassan O. J. Morad and James P. Catt, imphatec closed an oversubscribed £1.5M seed round led by SynBioVen in October 2026 to move toward human clinical trials.","url":"https://imphatec.com/","is_stealth":false,"normalized_domain":"imphatec.com","normalized_url_key":"imphatec.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://img1.wsimg.com/isteam/ip/7cb7ac2b-e712-4b76-a2f5-f509fe9d953f/For%20general%20use%20in%20decks.png/:/rs=w:152,h:152,m","links":[{"label":"X","url":"https://x.com/imphatecltd","platform":"x"},{"label":"Instagram","url":"https://www.instagram.com/imphatec/","platform":"instagram"},{"label":"BIA: £1.5M seed round led by SynBioVen","url":"https://www.bioindustry.org/resource/imphatec-closes-oversubscribed--1-5m-seed-round-led-by-synbioven.html"}],"entry_points":[{"kind":"homepage","url":"https://imphatec.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://imphatec.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"acc341dc-fb63-4e63-b0fd-37e183fa4ae8"},"categories":["Healthcare","Biotech","Medical Devices"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/imphatec-ltd","contact_email":null,"added_at":"2026-11-01T19:17:56.596Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-01T19:17:56.596Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-devices","name":"Medical Devices","note":null,"profile_url":"/industries/medical-devices"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-01T19:17:56.596Z","updated_at":"2026-11-01T19:17:56.596Z"}},{"listing_type":"company","name":"Setara Biosciences","slug":"setara-biosciences","tagline":"Genetics-driven precision medicines for severe rare diseases","description":"Setara Biosciences is a San Diego clinical-stage biotechnology company using human genetics to develop precision medicines for severe rare diseases. It was formed after Jazz Pharmaceuticals acquired Actio Biosciences and is advancing Actio's remaining pipeline, led by STAR-0871, an oral small-molecule TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C and overactive bladder, plus earlier discovery programs. In October 2026 it announced a $90 million Series A from investors including Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures and Jazz Pharmaceuticals.","url":"https://www.setarabiosciences.com/","is_stealth":false,"normalized_domain":"setarabiosciences.com","normalized_url_key":"setarabiosciences.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[],"entry_points":[{"kind":"homepage","url":"https://www.setarabiosciences.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.setarabiosciences.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Healthcare","Rare Diseases"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/setara-biosciences/","contact_email":null,"added_at":"2026-10-31T10:22:26.476Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-31T10:53:44.947Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"rare-diseases","name":"Rare Diseases","note":null,"profile_url":"/industries/rare-diseases"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-31T10:22:26.476Z","updated_at":"2026-10-31T10:22:26.476Z"}},{"listing_type":"company","name":"PopVax","slug":"popvax","tagline":"Indian full-stack biotech building ML-designed RNA vaccines and personalised cancer immunotherapies","description":"PopVax is a clinical-stage Indian biotechnology company that uses machine-learning-driven protein design to develop vaccines against infectious diseases such as Hepatitis C, Strep A, TB, influenza, HPV, malaria and COVID-19, and precision cancer immunotherapies for hard-to-treat solid tumours. Founded in late 2021, it has built its own mRNA architecture, ionizable lipids and lipid nanoparticle formulations, and fast-turnaround GMP production. Its open-source broadly protective COVID-19 vaccine, funded by Vitalik Buterin's Balvi and the Gates Foundation, entered a Phase I trial in Australia in August 2026. PopVax has raised more than $7.5 million in equity from Good Ventures and individual investors. In October 2026 it launched personalised cancer vaccine manufacturing at its RNA Foundry in Hyderabad.","url":"https://popvax.com/","is_stealth":false,"normalized_domain":"popvax.com","normalized_url_key":"popvax.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://popvax.com/assets/favicon.png","links":[{"label":"X","url":"https://x.com/PopVaxIndia","platform":"x"},{"label":"PopVax Chronicles (blog)","url":"https://chronicles.popvax.com/"}],"entry_points":[{"kind":"homepage","url":"https://popvax.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://popvax.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"8043b7cc-a385-4d7a-9aef-0f390b935d5b"},"categories":["Biotech","Vaccines","AI"],"stage":null,"founded_year":null,"location":"Hyderabad, India","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/popvax","contact_email":null,"added_at":"2026-10-30T22:20:00.906Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-30T22:20:43.830Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"vaccines","name":"Vaccines","note":null,"profile_url":"/industries/vaccines"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-30T22:20:00.906Z","updated_at":"2026-10-30T22:20:00.906Z"}},{"listing_type":"company","name":"The Biological Computing Co.","slug":"the-biological-computing-co","tagline":"Turns discoveries from living neurons into software that makes AI models faster and cheaper","description":"The Biological Computing Co. (TBC) is a San Francisco applied biological computing company. It grows living neurons in its lab, measures how they process information, and turns the computational principles it finds into proprietary software that makes existing AI models more efficient without retraining; the neurons stay in the lab and customers run the software on standard AI hardware. On October 30, 2026 it publicly launched TBC mischief 1, an image-to-video model built on Wan 2.2 that it says generates video five times faster at 80% lower inference cost, available on fal and OpenRouter. The company has also announced a collaboration with AWS and is working on applications in language models and physical AI. Alex Ksendzovsky is CEO and co-founder.","url":"https://www.tbc.co/","is_stealth":false,"normalized_domain":"tbc.co","normalized_url_key":"tbc.co","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/6a5e313cdc30c3120fae4fd7/6a5e313cdc30c3120fae4ff7_tbc-256px.jpg","links":[{"label":"X","url":"https://x.com/biocomputingco","platform":"x"},{"label":"Instagram","url":"https://www.instagram.com/biocomputingco","platform":"instagram"}],"entry_points":[{"kind":"homepage","url":"https://www.tbc.co/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.tbc.co/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"c26cece3-afd1-4ae0-abfb-c9f22e0f0b41"},"categories":["AI","Biotech","Generative Video"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/biological-black-box-bbb-inc/","contact_email":null,"added_at":"2026-10-30T19:16:44.386Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-30T19:17:48.363Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"generative-video","name":"Generative Video","note":null,"profile_url":"/industries/generative-video"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-30T19:16:44.386Z","updated_at":"2026-10-30T19:16:44.386Z"}},{"listing_type":"company","name":"Dren Bio","slug":"dren-bio","tagline":"Clinical-stage biotech developing first-in-class antibody therapies for cancer and autoimmune disease","description":"Dren Bio is a clinical-stage biotechnology company in San Carlos, California, developing first-in-class antibody therapeutics for cancer and autoimmune diseases. Its lead program, dibotatug (DR-01), is a CD94-targeting antibody for rare blood cancers and other hematologic and autoimmune diseases. In October 2026 it announced an oversubscribed $350 million private financing co-led by Juvia Group and Lightspeed Venture Partners to fund late-stage development, regulatory submission and commercial launch of dibotatug and to advance its broader pipeline.","url":"https://www.drenbio.com/","is_stealth":false,"normalized_domain":"drenbio.com","normalized_url_key":"drenbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.drenbio.com/assets/img/apple-icon.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.drenbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.drenbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"08bad09d-d8ce-4d36-a188-74cf4f7eba66"},"categories":["Biotech","Therapeutics"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-30T16:17:12.236Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-30T16:17:12.236Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-30T16:17:12.236Z","updated_at":"2026-10-30T16:17:12.236Z"}},{"listing_type":"company","name":"ALLOX","slug":"allox","tagline":"Experimental-first, AI-enabled platform for discovering allosteric drug targets","description":"ALLOX (Allostery Exploration Technologies, S.L.) is a Barcelona biotechnology company and spin-out of the Centre for Genomic Regulation (CRG). It combines high-throughput genetics, experimental biology and AI to map the functional hotspots that govern protein folding and interactions, measuring the effects of thousands of mutations in parallel to reveal allosteric, orthosteric and other regulatory sites. It uses this to design selective small molecules against historically hard-to-drug targets such as intracellular protein-protein interactions and transcription factors. Co-founders include Ben Lehner, Júlia Domingo, Pablo Baeza and Andre Faure. On October 29, 2026 it closed a $10.5M (€9.4M) seed round led by Asabys (Sabadell Asabys II) with CDTI and the Institut Català de Finances.","url":"https://www.allox.bio/","is_stealth":false,"normalized_domain":"allox.bio","normalized_url_key":"allox.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.allox.bio/images/img-logotipo-black@2x.webp","links":[{"label":"Seed announcement (GlobeNewswire, Oct 29 2026)","url":"https://www.globenewswire.com/news-release/2026/10/29/3390985/0/en/allox-closes-10-5m-seed-financing-and-appoints-morten-graugaard-as-chair-to-scale-allosteric-drug-discovery-platform-and-build-pipeline.html"},{"label":"ALLOX on X","url":"https://x.com/alloxbio","platform":"x"}],"entry_points":[{"kind":"homepage","url":"https://www.allox.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.allox.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"3f938e73-26bb-4dcd-a2c5-8c15ac418c3f"},"categories":["Biotech","Drug Discovery","AI"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/allox-bio/","contact_email":null,"added_at":"2026-10-29T13:22:49.911Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-29T13:24:41.268Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-29T13:22:49.911Z","updated_at":"2026-10-29T13:22:49.911Z"}},{"listing_type":"company","name":"Safer Human Medicine","slug":"safer-human-medicine","tagline":"Building a domestic US supply of specific-pathogen-free research primates for biomedical research","description":"Safer Human Medicine (SHM) is a US company that supplies specific-pathogen-free (SPF) non-human primates, including macaques, for biomedical and preclinical research, aiming to provide a sustainable domestic supply amid the US research primate shortage. Its services include client-owned breeding colonies and importation and quarantine coordination, with an emphasis on animal-welfare standards. It is backed by 8VC.","url":"https://saferhm.com/","is_stealth":false,"normalized_domain":"saferhm.com","normalized_url_key":"saferhm.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://saferhm.com/wp-content/uploads/2025/06/Primary-Logo.png","links":[],"entry_points":[{"kind":"homepage","url":"https://saferhm.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://saferhm.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"bcc33a1c-fdbb-4566-805c-9b4c16620cee"},"categories":["Biotech","Life Sciences","Research Services"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/safer-human-medicine/","contact_email":null,"added_at":"2026-10-29T01:20:36.083Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-29T01:21:57.007Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"research-services","name":"Research Services","note":null,"profile_url":"/industries/research-services"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-29T01:20:36.083Z","updated_at":"2026-10-29T01:20:36.083Z"}},{"listing_type":"company","name":"Formation Bio","slug":"formation-bio","tagline":"Tech-driven, AI-native pharma company that acquires and develops clinical-stage drugs","description":"Formation Bio is a tech-driven, AI-native pharmaceutical company that aims to bring new treatments to patients faster by acquiring and developing clinical-stage assets with its own technology platform. Formerly known as TrialSpark, it was co-founded by Benjamine Liu and Linhao Zhang. In October 2026 it announced a $600M Drug Development Accelerator Fund to acquire and advance Phase 1 and Phase 2 drug programs.","url":"https://www.formation.bio/","is_stealth":false,"normalized_domain":"formation.bio","normalized_url_key":"formation.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.formation.bio/touch-icon.png","links":[{"label":"X","url":"https://x.com/formationbio","platform":"x"},{"label":"YouTube","url":"https://www.youtube.com/@FormationBio","platform":"youtube"}],"entry_points":[{"kind":"homepage","url":"https://www.formation.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.formation.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"75d4b4a9-ea01-4f36-ad33-3b8540e48449"},"categories":["Biotech","Drug Development","Artificial Intelligence"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/formationbio/","contact_email":null,"added_at":"2026-10-28T22:18:44.905Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-28T22:20:18.063Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-28T22:18:44.905Z","updated_at":"2026-10-28T22:18:44.905Z"}},{"listing_type":"company","name":"Caravel Bio","slug":"caravel-bio","tagline":"Data engine for AI protein engineering, testing millions of protein designs in parallel","description":"Caravel Bio is a Portland, Oregon startup building a data engine for the biomolecular frontier. It tests millions of protein designs in parallel at a fraction of a cent each, using cell-free synthesis, microfluidic droplets and spore display, to generate training data for AI protein engineering, including proteins with non-canonical amino acids. It is led by founder and CEO Trevor Nicks and won a $1.25M NSF SBIR Phase II grant in October 2026.","url":"https://www.caravel.bio/","is_stealth":false,"normalized_domain":"caravel.bio","normalized_url_key":"caravel.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://images.squarespace-cdn.com/content/6a090cf0cec7692c6e4e379f/eb39c708-d8cb-4e35-bf9d-de35501eec58/Full+Logo+-+Light+Gradient.png?content-type=image%2Fpng","links":[],"entry_points":[{"kind":"homepage","url":"https://www.caravel.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.caravel.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"28a45e0d-5e53-4733-95ed-7c6c8661a065"},"categories":["Biotech","Protein Engineering","Artificial Intelligence"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/caravel-bio","contact_email":null,"added_at":"2026-10-28T22:19:08.505Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-28T22:19:59.248Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"protein-engineering","name":"Protein Engineering","note":null,"profile_url":"/industries/protein-engineering"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-28T22:19:08.505Z","updated_at":"2026-10-28T22:19:08.505Z"}},{"listing_type":"company","name":"Samplix","slug":"samplix","tagline":"Droplet microfluidics for functional single-cell analysis","description":"Samplix is a Danish biotech company headquartered in Birkerød, founded in 2013, that develops droplet microfluidics technology for high-throughput, function-first single-cell analysis. Its Xdrop platform encapsulates living cells and assay reagents in double-emulsion droplets compatible with standard flow cytometry and cell sorting, used in antibody discovery, immunotherapy and cell line development. In October 2026 it announced a EUR 25 million first close of a financing round led by WLanholding GmbH.","url":"https://samplix.com/","is_stealth":false,"normalized_domain":"samplix.com","normalized_url_key":"samplix.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://samplix.com/files/$images/Samplix_droplets_blue_RGB.png","links":[{"label":"YouTube","url":"https://www.youtube.com/@samplix4497"},{"label":"Financing announcement (EU-Startups)","url":"https://www.eu-startups.com/2026/10/danish-biotech-samplix-secures-e25-million-in-first-close-of-financing-round-to-scale-antibody-discovery/"}],"entry_points":[{"kind":"homepage","url":"https://samplix.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://samplix.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"8115c26f-235f-4e7f-b883-e8979a2f6c9b"},"categories":["Biotech","Life Sciences","Drug Discovery"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/samplix-aps/","contact_email":null,"added_at":"2026-10-28T07:19:15.099Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-28T07:21:08.886Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-28T07:19:15.099Z","updated_at":"2026-10-28T07:19:15.099Z"}},{"listing_type":"company","name":"Atlas Bio","slug":"atlas-bio","tagline":"In silico clinical trials powered by a foundation model of human biology","description":"Atlas Bio is a Basel-based tech-bio company building a foundation AI model trained on roughly 2 million human RNA readouts to run in silico clinical trials, simulating patient-level efficacy and safety before Phase II so biopharma teams can decide what to advance, acquire or expand. Founded in 2024 by Simon Romanski and Sebastian Bayer, it launched from stealth in October 2026 with a $10 million seed led by Creandum plus a $2.5 million pre-seed led by First Momentum Ventures and LEA Partners.","url":"https://atlas.bio/","is_stealth":false,"normalized_domain":"atlas.bio","normalized_url_key":"atlas.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://atlas.bio/apple-touch-icon.png","links":[{"label":"Seed announcement (Tech.eu)","url":"https://tech.eu/2026/10/27/swiss-startup-atlas-bio-secures-125m-to-tackle-drug-developments-70-failure-rate-and-move-beyond-animal-testing/"}],"entry_points":[{"kind":"homepage","url":"https://atlas.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://atlas.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"5669738a-a850-4ab0-a6c4-78594f53e866"},"categories":["AI","Biotech","Drug Development"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/atlasbio/","contact_email":null,"added_at":"2026-10-28T04:17:48.423Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-28T04:19:08.237Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-28T04:17:48.423Z","updated_at":"2026-10-28T04:17:48.423Z"}},{"listing_type":"company","name":"Omabit","slug":"omabit","tagline":"AI for life science R&D","description":"Omabit is a San Francisco company building AI to support scientific decision-making in drug development. It analyzes a life science company's own clinical, genomic and other R&D data, checks each finding against published research and writes it up, initially for clinical development, biomarker and translational teams. It announced $2M in seed financing led by Bright Ventures in October 2026.","url":"https://www.omabit.com/","is_stealth":false,"normalized_domain":"omabit.com","normalized_url_key":"omabit.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[],"entry_points":[{"kind":"homepage","url":"https://www.omabit.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.omabit.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["AI","Biotech","Healthcare"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-27T22:24:21.175Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-27T22:24:21.175Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-27T22:24:21.175Z","updated_at":"2026-10-27T22:24:21.175Z"}},{"listing_type":"company","name":"DropGenie","slug":"dropgenie","tagline":"Miniaturized CRISPR gene editing workflows for primary cells","description":"DropGenie is a Montreal and Boston biotechnology company that miniaturizes gene editing workflows on a digital microfluidics chip. Its platform runs high-throughput CRISPR edits directly on primary patient cells while using far fewer cells and reagents than conventional methods, aiming to lower costs and speed up turnaround for cell therapy, functional genomics and AI-driven discovery. Its seed+ round was led by Skeleton Key with Merck Global Health Innovation Fund, CQDM, Real Ventures and Anges Québec, and BDC Capital's Thrive Fund later joined, bringing the round to US$5M.","url":"https://dropgenie.com/","is_stealth":false,"normalized_domain":"dropgenie.com","normalized_url_key":"dropgenie.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://dropgenie.com/wp-content/uploads/2025/04/cropped-favicon_dropgenie-1-192x192.png","links":[{"label":"BetaKit: DropGenie raises US$5M backed by BDC","url":"https://betakit.com/dropgenie-raises-5-million-usd-backed-by-bdc-to-speed-up-biological-discovery/"}],"entry_points":[{"kind":"homepage","url":"https://dropgenie.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://dropgenie.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"02bafe89-63d6-4d23-b10d-b604486e1571"},"categories":["Biotech","Gene Editing","Life Sciences Tools"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-26T10:18:28.457Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-26T10:19:15.335Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-editing","name":"Gene Editing","note":null,"profile_url":"/industries/gene-editing"},{"kind":"industry","slug":"life-sciences-tools","name":"Life Sciences Tools","note":null,"profile_url":"/industries/life-sciences-tools"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-26T10:18:28.457Z","updated_at":"2026-10-26T10:18:28.457Z"}},{"listing_type":"company","name":"Reflector Bio","slug":"reflector-bio","tagline":"In silico phenotypic screening that predicts how compounds perform in cells","description":"Reflector Bio is a New York techbio company building a biological foundation model for AI drug discovery that predicts a compound's efficacy, function and safety signals in living cells, complementing structure-based binding tools. The model is trained on lab data from millions of experiments and tailored to each client's program to help biopharma teams prioritise compounds and experiments. It emerged from stealth in October 2026. Founder and CEO Yuge Ji is an MIT-trained computational biologist who previously built drug discovery models at Flagship Pioneering's Cellarity.","url":"https://reflector.bio/","is_stealth":false,"normalized_domain":"reflector.bio","normalized_url_key":"reflector.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://reflector.bio/assets/icons/cropped-reflector-bio-favicon-192x192.png","links":[{"label":"Emerges from stealth announcement","url":"https://reflector.bio/news/emerges-from-stealth/"}],"entry_points":[{"kind":"homepage","url":"https://reflector.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://reflector.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2acd185b-688a-48f6-95e8-c1355a1d037f"},"categories":["Biotech","Artificial Intelligence","Drug Discovery"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/reflectorbio","contact_email":null,"added_at":"2026-10-26T01:24:03.779Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-26T01:26:17.476Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-26T01:24:03.779Z","updated_at":"2026-10-26T01:24:03.779Z"}},{"listing_type":"company","name":"Aureka Biotechnologies","slug":"aureka-biotechnologies","tagline":"AI-native TechBio company using foundation models and autonomous labs for drug discovery","description":"Aureka Biotechnologies is a TechBio company based in Laguna Hills, California and Shanghai that combines agentic AI, biological foundation models and end-to-end lab automation to run closed-loop Generate-Test-Learn-Optimize cycles for drug discovery. It is building an internal pipeline of antibody therapeutics targeting cardiometabolic, inflammatory and CNS and aging-related diseases. Its products include Aureka Prism, an enterprise AI agent for pharma R&D, and OpenDDE, an open-weight all-atom biomolecular foundation model. In August 2026 it announced a US$100 million Series B with Granite Asia funding the first tranche, bringing total funding to nearly US$200 million.","url":"https://aurekabio.com/","is_stealth":false,"normalized_domain":"aurekabio.com","normalized_url_key":"aurekabio.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"X","url":"https://x.com/AurekaBio","platform":"x"},{"label":"GitHub (aurekaresearch)","url":"https://github.com/aurekaresearch","platform":"github"}],"entry_points":[{"kind":"homepage","url":"https://aurekabio.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://aurekabio.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Artificial Intelligence","Healthcare"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/aurekabio","contact_email":null,"added_at":"2026-10-25T22:23:41.995Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-26T01:24:53.998Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-25T22:23:41.995Z","updated_at":"2026-10-25T22:23:41.995Z"}},{"listing_type":"company","name":"Arctic Therapeutics","slug":"arctic-therapeutics","tagline":"Clinical-stage biopharma turning human genetic discoveries into treatments for dementia, skin and autoimmune diseases","description":"Arctic Therapeutics (ATx) is an Icelandic clinical-stage biopharmaceutical company that translates genetic discoveries into new treatments for diseases with significant unmet medical need. Its lead programmes are AT-001, an oral treatment studied in hereditary cerebral amyloid angiopathy and Alzheimer's disease, and AT-004, a topical anti-inflammatory for skin diseases that has completed a Phase IIa acne study. Clinical operations are in Akureyri, with commercial operations in Reykjavik and Philadelphia. In October 2026 it closed an oversubscribed US$21.5 million financing led by Pekron, Sanos Group, Kaldbakur and Landvaettir to advance AT-002 and AT-003 toward the clinic, following an approximately US$31 million Series A.","url":"https://www.arctictherapeutics.com/","is_stealth":false,"normalized_domain":"arctictherapeutics.com","normalized_url_key":"arctictherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.arctictherapeutics.com/wp-content/uploads/2025/05/cropped-arctic_favicon-1-192x192.webp","links":[],"entry_points":[{"kind":"homepage","url":"https://www.arctictherapeutics.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.arctictherapeutics.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"41066e44-2051-405d-8bdd-4ab14df54eee"},"categories":["Biotech","Healthcare","Drug Discovery","Genomics"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/arctic-therapeutics-at/","contact_email":null,"added_at":"2026-10-25T16:26:16.990Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-25T19:45:14.361Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-25T16:26:16.990Z","updated_at":"2026-10-25T16:26:16.990Z"}},{"listing_type":"company","name":"Star Therapeutics","slug":"star-therapeutics","tagline":"Biotech discovering antibody therapies for hematology, immunology and other diseases with unmet need","description":"Star Therapeutics is a South San Francisco biotechnology company focused on discovering and developing therapies for diseases with significant unmet need, with a focus on antibody therapies for hematological and immune conditions. In July 2026 Incyte completed the acquisition of Star's subsidiary Vega Therapeutics (lead program latarcibart, in Phase 3 for von Willebrand disease) in a deal valued at up to $2 billion, and in September 2026 Star's spinout Electra Therapeutics listed on Nasdaq. In October 2026 Star announced a $200 million private financing co-led by OrbiMed and Janus Henderson Investors to advance its preclinical programs into the clinic.","url":"https://star-therapeutics.com/","is_stealth":false,"normalized_domain":"star-therapeutics.com","normalized_url_key":"star-therapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://star-therapeutics.com/wp-content/uploads/2022/02/Group-6210.png","links":[],"entry_points":[{"kind":"homepage","url":"https://star-therapeutics.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://star-therapeutics.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"8cf78db6-619f-4cff-89cf-b276c6c544b6"},"categories":["Biotech","Therapeutics","Healthcare"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-24T07:19:10.751Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-24T07:39:54.339Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-24T07:19:10.751Z","updated_at":"2026-10-24T07:19:10.751Z"}},{"listing_type":"company","name":"Pathos","slug":"pathos","tagline":"AI-enabled clinical-stage biotech building a new development engine for precision oncology","description":"Pathos (Pathos AI) is a New York-headquartered, AI-enabled clinical-stage biotech company. It integrates AI technology, biological modeling and a large collection of oncology patient data to make clinical trials smarter and more precise, aiming to select the right patients for therapies and build a new development engine for precision oncology through multimodal data, biological modeling and biopharma partnerships. In October 2026 Pathos completed a $237 million Series E financing led by Bristol Myers Squibb.","url":"https://www.pathos.com/","is_stealth":false,"normalized_domain":"pathos.com","normalized_url_key":"pathos.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://irp.cdn-website.com/8e545b68/dms3rep/multi/pathos-brandmark.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.pathos.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.pathos.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"3ea4ec41-446c-4127-a30f-bb7a8a1b4f0f"},"categories":["Biotech","AI","Healthcare","Oncology","Drug Development"],"stage":"series-b+","founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/pathos-ai/","contact_email":null,"added_at":"2026-10-23T19:25:59.630Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-23T19:30:14.673Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-23T19:25:59.630Z","updated_at":"2026-10-23T19:25:59.630Z"}},{"listing_type":"company","name":"Warp Sciences","slug":"warp-sciences","tagline":"U.S. chemistry CRO combining expert chemists, AI and robotics to make and test molecules for drug discovery","description":"Warp Sciences is a San Francisco company building a U.S.-based preclinical chemistry contract research organization (CRO) for biotech and pharma teams. It brings expert chemists, AI and robotics together to make and test the research compounds drug discovery teams need, in labs built for increasing automation so experimental data can train better scientific AI. Warp has no drug pipeline of its own. It was co-founded by Kevin Weil (CEO, formerly Chief Product Officer and VP of Science at OpenAI), DJ Patil (COO, first U.S. Chief Data Scientist), Sol Reisberg (CSO, medicinal chemist, co-founder of Terremoto Biosciences) and Manohar Paluri (CTO, FAIR co-founder and former VP at Meta Superintelligence Labs). On October 22, 2026 it emerged from stealth with $215 million in funding led by Lightspeed, with Premji Invest, Mayfield, IVP, Lux, Menlo Ventures and others participating.","url":"https://warp.xyz/","is_stealth":false,"normalized_domain":"warp.xyz","normalized_url_key":"warp.xyz","parent_slug":null,"parent":null,"type_data":{},"logo":"https://warp.xyz/apple-touch-icon.png","links":[{"label":"X","url":"https://x.com/warpsciences","platform":"x"},{"label":"Launch press release (Business Wire)","url":"https://www.businesswire.com/news/home/20261022200104/en/Warp-Sciences-Emerges-From-Stealth-With-%24215-Million-to-Build-U.S.-Chemistry-Services-for-Drug-Research"},{"label":"Why We're Backing Warp (Lightspeed)","url":"https://lsvp.com/stories/why-were-backing-warp/"}],"entry_points":[{"kind":"homepage","url":"https://warp.xyz/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://warp.xyz/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"c19b5339-2e98-42fa-8ba9-4c7da477adf2"},"categories":["Biotech","AI","Robotics","Drug Discovery","Life Sciences"],"stage":"series-a","founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/warp-sciences/","contact_email":null,"added_at":"2026-10-23T16:20:26.140Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-23T16:26:00.673Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"robotics","name":"Robotics","note":null,"profile_url":"/industries/robotics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-23T16:20:26.140Z","updated_at":"2026-10-23T16:20:26.140Z"}},{"listing_type":"company","name":"Pythag Tech","slug":"pythag-tech","tagline":"AI and data platform that optimizes cultivated meat production processes","description":"Pythag Tech is a New York-based data and technology company accelerating the future of cultivated meat. It uses AI models to directly drive large-scale laboratory experiments on the industry's three core cost drivers (growth media, cell line development and bioprocessing), with each experiment adding to a proprietary biological dataset that lets its models iteratively find parameters that optimize production and lower cost. Rather than producing meat itself, Pythag licenses its optimized production processes and insights to food companies and meat producers. In October 2026 it announced $4.25 million in seed funding led by Azolla Ventures with participation from Endurance28 and other institutional investors.","url":"https://www.pythagtech.com/","is_stealth":false,"normalized_domain":"pythagtech.com","normalized_url_key":"pythagtech.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.pythagtech.com/favicon.png","links":[{"label":"Seed funding announcement (GlobeNewswire)","url":"https://www.globenewswire.com/news-release/2026/10/22/3386423/0/en/ai-for-cultivated-meat-pythag-tech-closes-4-25-million-in-seed-funding.html"}],"entry_points":[{"kind":"homepage","url":"https://www.pythagtech.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.pythagtech.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"0f461c8b-00a5-495c-a6a7-3596b1c59c59"},"categories":["Food Tech","Cultivated Meat","AI","Biotech"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-23T04:19:51.010Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-23T04:19:51.010Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cultivated-meat","name":"Cultivated Meat","note":null,"profile_url":"/industries/cultivated-meat"},{"kind":"industry","slug":"food-tech","name":"Food Tech","note":null,"profile_url":"/industries/food-tech"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-23T04:19:51.010Z","updated_at":"2026-10-23T04:19:51.010Z"}},{"listing_type":"company","name":"Warhound","slug":"warhound","tagline":"Advanced canine genetics and cybernetics platform for elite working dogs","description":"Warhound is a Texas-based defense technology company conceived by Colossal Biosciences CEO Ben Lamm and Anduril co-founder Palmer Luckey, and led by CEO David Spirk, previously the U.S. Department of Defense's first chief data officer. It aims to rebuild America's domestic supply of working dogs for the military, law enforcement and emergency response by biobanking and cloning top-performing dogs, using licensed Colossal genetics technology to improve traits such as health and performance, and equipping the dogs with Anduril hardware and software. Its training programs are certified by the American Humane Society. Warhound emerged from stealth in October 2026 with a $200 million seed round at a reported $1.2 billion valuation, backed by investors including Sequoia Capital, In-Q-Tel, ARK Invest, 8VC and Lux Capital.","url":"https://warhound.com/","is_stealth":false,"normalized_domain":"warhound.com","normalized_url_key":"warhound.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://warhound.com/favicon.ico","links":[{"label":"Launch announcement (PR Newswire)","url":"https://www.prnewswire.com/news-releases/warhound-launches-with-200-million-to-rebuild-americas-military-working-dog-supply-using-advanced-genetics-and-defense-technology-302917498.html"},{"label":"TechCrunch: Warhound raises $200M","url":"https://techcrunch.com/2026/10/22/ben-lamm-raises-200m-for-warhound-to-engineer-war-dogs-and-arm-them-with-anduril-gear/"}],"entry_points":[{"kind":"homepage","url":"https://warhound.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://warhound.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Defense Tech","Biotech","Genetics","Animal Health"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-23T01:19:12.248Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-23T01:19:12.248Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"animal-health","name":"Animal Health","note":null,"profile_url":"/industries/animal-health"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"defense-tech","name":"Defense Tech","note":null,"profile_url":"/industries/defense-tech"},{"kind":"industry","slug":"genetics","name":"Genetics","note":null,"profile_url":"/industries/genetics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-23T01:19:12.248Z","updated_at":"2026-10-23T01:19:12.248Z"}},{"listing_type":"company","name":"Familiar Therapeutics","slug":"familiar-therapeutics","tagline":"Brings proven human medicines to dogs and cats through FDA approval","description":"Familiar Therapeutics is a Redwood City, California biotech company that licenses the veterinary rights to drugs already researched for human disease from pharmaceutical and biotech partners, then leads the clinical development, manufacturing and FDA Center for Veterinary Medicine work needed to get them approved for dogs and cats. Founded in 2026 by Elizabeth Iorns and Dan Knox (co-founders of Science Exchange), it says it has built four lead and nine earlier-stage programs spanning oncology, neurology, cardiology, respiratory disease and immunology. Its lead program, FAM-010, targets canine hemangiosarcoma, a cancer with no FDA-approved treatment, with a pilot study planned at the University of Illinois College of Veterinary Medicine. It launched in October 2026 with a $5 million seed round led by Pioneer Fund, Icehouse Ventures and BreakTHRU.","url":"https://familiartx.com/","is_stealth":false,"normalized_domain":"familiartx.com","normalized_url_key":"familiartx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://familiartx.com/favicon.ico","links":[{"label":"X","url":"https://x.com/FamiliarTx","platform":"x"},{"label":"Launch announcement (Business Wire via Yahoo Finance)","url":"https://finance.yahoo.com/healthcare/articles/familiar-therapeutics-launches-5-million-121200253.html"}],"entry_points":[{"kind":"homepage","url":"https://familiartx.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://familiartx.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Animal Health","Veterinary","Drug Development"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/familiartx/","contact_email":null,"added_at":"2026-10-22T22:20:29.321Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-22T22:21:24.739Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"animal-health","name":"Animal Health","note":null,"profile_url":"/industries/animal-health"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"veterinary","name":"Veterinary","note":null,"profile_url":"/industries/veterinary"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-22T22:20:29.321Z","updated_at":"2026-10-22T22:20:29.321Z"}},{"listing_type":"company","name":"Orchestra Bio","slug":"orchestra-bio","tagline":"Intelligent management platform helping biotech and pharma teams plan and run drug development","description":"Orchestra Bio built an intelligent management platform that helps research and development organizations unify planning, automate operations and reduce the risks that derail drug development programs across discovery, preclinical, manufacturing and clinical work. Founded about four years ago by Ashoka Rajendra, it announced on October 20, 2026 that it is joining OpenAI, where its platform will be combined with OpenAI's life sciences tools.","url":"https://orchestra.bio/","is_stealth":false,"normalized_domain":"orchestra.bio","normalized_url_key":"orchestra.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://framerusercontent.com/images/o2qgMaiR03x0g2F2MJxQZR2UkAk.png","links":[{"label":"SiliconANGLE: OpenAI acquires Orchestra Bio","url":"https://siliconangle.com/2026/10/20/openai-acquires-orchestra-bio-to-bring-ai-agents-into-drug-development/"}],"entry_points":[{"kind":"homepage","url":"https://orchestra.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://orchestra.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"ddfee7e7-5601-46fc-8115-d777523d1efe"},"categories":["Biotech","AI","Life Sciences","R&D Software"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-21T04:30:32.727Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-21T04:30:49.055Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"r-and-d-software","name":"R&D Software","note":null,"profile_url":"/industries/r-and-d-software"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-21T04:30:32.727Z","updated_at":"2026-10-21T04:30:32.727Z"}},{"listing_type":"company","name":"Sophont","slug":"sophont","tagline":"Frontier medical AI lab building open multimodal foundation models, benchmarks and Holon-S1 for pathology","description":"Sophont is a medical AI lab founded in 2025 that is building towards open medical superintelligence for clinicians: multimodal foundation models that reason across pathology slides, brain scans, clinical notes and labs, plus open frameworks and benchmarks such as nanopath and Medmarks. Its Holon-S1 model predicts spatial gene expression from routine H&E pathology slides. Sophont is led by CEO Tanishq Abraham, founder of the MedARC research community, and CTO Paul Scotti, and announced $9.22 million in combined pre-seed and seed funding led by Kindred Ventures.","url":"https://sophont.med/","is_stealth":false,"normalized_domain":"sophont.med","normalized_url_key":"sophont.med","parent_slug":null,"parent":null,"type_data":{},"logo":"https://sophont.med/favicon.png","links":[],"entry_points":[{"kind":"homepage","url":"https://sophont.med/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"github","url":"https://github.com/SophontAI","audience":"any","primary":false,"listed_by":"community","derived_from":"github","on_listing_domain":false}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://sophont.med/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"64b1b756-9676-4874-9583-4068e1be4f13"},"categories":["AI","Healthcare","Medical AI","Biotech","Open Source"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/SophontAI","github":"https://github.com/SophontAI","linkedin":"https://www.linkedin.com/company/sophont/","contact_email":null,"added_at":"2026-10-21T01:21:52.844Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-21T01:22:33.891Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-ai","name":"Medical AI","note":null,"profile_url":"/industries/medical-ai"},{"kind":"industry","slug":"open-source","name":"Open Source","note":null,"profile_url":"/industries/open-source"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-21T01:21:52.844Z","updated_at":"2026-10-21T01:21:52.844Z"}},{"listing_type":"company","name":"Cellbox Solutions","slug":"cellbox-solutions","tagline":"Warm-chain logistics for living cells: transportable CO2 incubators and live-cell shipment services","description":"Cellbox Solutions is a German warm-chain logistics technology company that keeps living biological materials alive in transit. It combines transportable CO2 incubators (the Cellbox Go and Shipper lines for ground and air transport) with logistics services and workflow integration, maintaining physiological temperature and CO2 conditions for drug discovery, cell and gene therapy, clinical and IVF workflows. Founder and CEO Prof. Dr. Kathrin Adlkofer leads the company. In October 2026 EU-Startups reported Cellbox completed the final closing of its Series A at €5 million in total, with members of Baltic Business Angels Invest joining existing investors NRW.BANK and Fraunhofer Venture.","url":"https://cellbox-solutions.com/","is_stealth":false,"normalized_domain":"cellbox-solutions.com","normalized_url_key":"cellbox-solutions.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cellbox-solutions.com/assets/img/icons/apple-icon-180x180.png","links":[{"label":"YouTube","url":"https://www.youtube.com/@cellboxsolutions","platform":"youtube"}],"entry_points":[{"kind":"homepage","url":"https://cellbox-solutions.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://cellbox-solutions.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"204a4db3-f6ab-49e2-bdc9-21911c7e055b"},"categories":["Biotech","Life Sciences","Logistics","Hardware"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/Cellbox_","github":null,"linkedin":"https://www.linkedin.com/company/cellbox-solutions/","contact_email":null,"added_at":"2026-10-20T19:28:05.131Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-20T20:15:04.273Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"hardware","name":"Hardware","note":null,"profile_url":"/industries/hardware"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"logistics","name":"Logistics","note":null,"profile_url":"/industries/logistics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-20T19:28:05.131Z","updated_at":"2026-10-20T19:28:05.131Z"}},{"listing_type":"company","name":"Radical Numerics","slug":"radical-numerics","tagline":"AI lab building toward general biological intelligence with Omnii-1, a multimodal genome language model","description":"Radical Numerics is a next-generation AI lab building toward general biological intelligence: AI that can interpret, generate and predict biology, with a dual mandate to advance biological intelligence and strengthen biodefense.","url":"https://www.radicalnumerics.ai/","is_stealth":false,"normalized_domain":"radicalnumerics.ai","normalized_url_key":"radicalnumerics.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.sanity.io/images/0g0784cc/production/0e8bb7df8e06b1514a4a7f7a7067e11d09b72291-1200x630.png","links":[{"label":"YouTube","url":"https://www.youtube.com/@RadicalNumerics","platform":"youtube"}],"entry_points":[{"kind":"homepage","url":"https://www.radicalnumerics.ai/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.radicalnumerics.ai/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2d041997-e156-496f-ba7c-7f57912ade6b"},"categories":["AI","Biotech","Life Sciences"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/RadicalNumerics","github":null,"linkedin":"https://www.linkedin.com/company/radical-numerics","contact_email":null,"added_at":"2026-10-20T19:53:13.993Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-20T20:14:42.857Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-20T19:53:13.993Z","updated_at":"2026-10-20T19:53:13.993Z"}},{"listing_type":"company","name":"Nouscom","slug":"nouscom","tagline":"Clinical-stage biotech developing off-the-shelf neoantigen cancer immunotherapies","description":"Nouscom is a Basel-based clinical-stage biotech founded in 2015 that develops next-generation neoantigen-targeted immunotherapies, with a focus on cancer interception. Its lead programme NOUS-209 is an investigational off-the-shelf neoantigen-based immunotherapy for people with Lynch Syndrome. Marina Udier is CEO. In October 2026 it closed an oversubscribed 120 million euro Series D co-led by M Ventures and Revelation Partners, with new investors Angelini Ventures, the EIB and Neva SGR and existing investors including 5AM Ventures, Versant Ventures and EQT Life Sciences.","url":"https://nouscom.com/","is_stealth":false,"normalized_domain":"nouscom.com","normalized_url_key":"nouscom.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Series D coverage (EU-Startups)","url":"https://www.eu-startups.com/2026/10/switzerlands-nouscom-bags-e120-million-to-bring-innovative-cancer-immunotherapy-closer-to-clinical-trials/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://nouscom.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://nouscom.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Oncology","Immunotherapy","Life Sciences"],"stage":"series-b+","founded_year":2015,"location":"Basel, Switzerland","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-19T10:41:55.498Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-19T10:41:55.498Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"immunotherapy","name":"Immunotherapy","note":null,"profile_url":"/industries/immunotherapy"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-19T10:41:55.498Z","updated_at":"2026-10-19T10:41:55.498Z"}},{"listing_type":"company","name":"Media City Scientific","slug":"media-city-scientific","tagline":"Chemically defined, animal-free replacement for fetal bovine serum in cell culture","description":"Media City Scientific is a family-owned company in the Southern Highlands of NSW, Australia, that makes chemically defined cell culture products. Its FRS Pioneer is an animal-free replacement for fetal bovine serum that drops into standard basal media, and GECKO is an animal-free adhesion protein mix for serum-free adherent cell culture. It is one of 16 startups in UNSW Founders' 2026 10x Accelerator cohort, which each received a A$100,000 pre-seed investment.","url":"https://www.mediacityscientific.com/","is_stealth":false,"normalized_domain":"mediacityscientific.com","normalized_url_key":"mediacityscientific.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.mediacityscientific.com/uploads/7/3/5/4/7354964/media-city-logo-transparent_orig.png","links":[{"label":"Startup Daily: UNSW 10x Accelerator first cheques to 16 startups","url":"https://www.startupdaily.net/advice/investing/before-vcs-a-university-writes-the-first-cheque/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://www.mediacityscientific.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.mediacityscientific.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"a56e04f5-9637-4204-8137-feec16a4520a"},"categories":["Biotech","Cell Culture","Life Science Tools"],"stage":"pre-seed","founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-18T19:27:57.071Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-18T19:27:57.071Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-culture","name":"Cell Culture","note":null,"profile_url":"/industries/cell-culture"},{"kind":"industry","slug":"life-science-tools","name":"Life Science Tools","note":null,"profile_url":"/industries/life-science-tools"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-18T19:27:57.071Z","updated_at":"2026-10-18T19:27:57.071Z"}},{"listing_type":"company","name":"Geney Bio","slug":"geney-bio","tagline":"Scalable, automated cell-processing platform for cell and gene therapy manufacturing","description":"Geney Bio is developing a scalable cell-processing platform designed to reduce the time, cost and risk of taking advanced therapies such as cell and gene therapies from process development to commercial-scale manufacturing. The platform, still under development, aims to cut process redevelopment and tech-transfer work as programmes scale, automate repetitive handling in a closed system, and use low-volume processing to reduce expensive reagent consumption; the company reports proof-of-concept testing that used about 50% less viral vector than a well-plate control with similar GFP expression. It targets therapy developers, translational and process development centres, and CDMOs. Geney Bio is in UNSW Founders' 2026 10x Accelerator (Health 10x) cohort, which each received a A$100,000 pre-seed investment.","url":"https://www.geneybio.com/","is_stealth":false,"normalized_domain":"geneybio.com","normalized_url_key":"geneybio.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Facebook","url":"https://www.facebook.com/geneybio","platform":"facebook"},{"label":"Startup Daily: UNSW 10x Accelerator first cheques to 16 startups","url":"https://www.startupdaily.net/advice/investing/before-vcs-a-university-writes-the-first-cheque/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://www.geneybio.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.geneybio.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Biotech","Cell and Gene Therapy","Biomanufacturing","Lab Automation"],"stage":"pre-seed","founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/geney-bio","contact_email":null,"added_at":"2026-10-18T13:47:38.229Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-18T13:47:38.229Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biomanufacturing","name":"Biomanufacturing","note":null,"profile_url":"/industries/biomanufacturing"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-and-gene-therapy","name":"Cell and Gene Therapy","note":null,"profile_url":"/industries/cell-and-gene-therapy"},{"kind":"industry","slug":"lab-automation","name":"Lab Automation","note":null,"profile_url":"/industries/lab-automation"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-18T13:47:38.229Z","updated_at":"2026-10-18T13:47:38.229Z"}},{"listing_type":"company","name":"Neela Biotech","slug":"neela-biotech","tagline":"AI-guided microbial upcycling of waste into feedstock for sustainable aviation fuel","description":"Neela Biotech is a Cambridge, UK startup converting food, agricultural and forestry waste into fatty acids, a precursor for HEFA-based sustainable aviation fuel (SAF), through an AI-guided Controlled Microbial Upcycling process. The technology builds on anaerobic digestion, so it can be deployed at existing biogas plants rather than new facilities, aiming to lower capital costs and give plant operators a new revenue stream. Founded by Dr Deepanshu Singh (CEO) and Friederike Nintzel (CTO), building on research from the University of Cambridge Department of Engineering, the company raised a £2.1 million pre-seed round in October 2026 led by Elbow Beach with Ascension, Cambridge Enterprise Ventures, Ventures Together and angels, to move to a pilot-scale trial at a biogas plant. It is part of the IAG innovation programme and has grant funding from Innovate UK and the Henry Royce Institute.","url":"https://www.neelabiotech.com/","is_stealth":false,"normalized_domain":"neelabiotech.com","normalized_url_key":"neelabiotech.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Cambridge Enterprise: Neela Biotech raises £2.1m (Oct 2026)","url":"https://www.enterprise.cam.ac.uk/news/neela-biotech-raises-2-1-million/","platform":"other"},{"label":"Tech Funding News: Neela Biotech raises £2.1M from Elbow Beach","url":"https://techfundingnews.com/cambridge-startup-neela-biotech-raises-2-1m-from-elbow-beach-to-turn-waste-into-jet-fuel-with-ai/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://www.neelabiotech.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.neelabiotech.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Deepanshu Singh","role":"Co-founder & CEO","person_slug":"deepanshu-singh-2tugkxt7yry1n","bio":null,"location":null,"links":[]},{"name":"Friederike Nintzel","role":"Co-founder & CTO","person_slug":"friederike-nintzel-36sizvyharni3","bio":null,"location":null,"links":[]}],"media":null,"categories":["Climate Tech","Synthetic Biology","Sustainable Aviation Fuel","Biotech"],"stage":"pre-seed","founded_year":null,"location":"Cambridge, UK","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/neela-biotech","contact_email":null,"added_at":"2026-10-18T10:27:45.547Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-18T10:27:45.547Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"climate-tech","name":"Climate Tech","note":null,"profile_url":"/industries/climate-tech"},{"kind":"industry","slug":"sustainable-aviation-fuel","name":"Sustainable Aviation Fuel","note":null,"profile_url":"/industries/sustainable-aviation-fuel"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-18T10:27:45.547Z","updated_at":"2026-10-18T10:27:45.547Z"}},{"listing_type":"company","name":"Number 8 Bio","slug":"number-8-bio","tagline":"Agricultural biotech making BetterFeed, a slow-release bolus that cuts methane from grazing cattle and sheep","description":"Number 8 Bio is an Australian agricultural biotechnology company working on how livestock are fed. Its product BetterFeed uses a proprietary organic small molecule, delivered as a slow-release bolus for grazing beef cattle and sheep, to inhibit enteric methane and redirect feed energy that would otherwise be lost to methane back into production; the company reports methane reductions of up to 50% in early beef cattle trials. It was co-founded by CEO Dr Tom Williams, previously a senior lecturer in metabolic engineering at Macquarie University, and Dr Alex Carpenter. In October 2026 it announced new investment from Uniseed and UniSuper alongside continued support from existing investor Innovation Victoria, and it has previously won a $1.7 million grant to scale and trial its capsules across Australia.","url":"https://www.number8.bio/","is_stealth":false,"normalized_domain":"number8.bio","normalized_url_key":"number8.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static1.squarespace.com/static/69b7249dff9d9d5d4cc741e6/t/69b7c8a397555d189ebed55f/1773652131273/number8bio_wordmark.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/number-8-bio/","platform":"linkedin"},{"label":"LinkedIn: investment from Uniseed and UniSuper (Oct 2026)","url":"https://www.linkedin.com/posts/number-8-bio_excited-to-announce-continued-support-from-activity-7513726514723549184-_pcO","platform":"linkedin"},{"label":"New methane-reducing bolus (company news)","url":"https://www.number8.bio/resources/new-methane-reducing-bolus","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://www.number8.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.number8.bio/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Tom Williams","role":"Co-founder & CEO","person_slug":"tom-williams-3ra7z2qvychxw","bio":null,"location":null,"links":[]},{"name":"Alex Carpenter","role":"Co-founder","person_slug":"alex-carpenter-0kqb81bcnacqm","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"5fcc887a-fd9f-4342-90e4-431b018337b6"},"categories":["Agtech","Climate Tech","Biotech","Livestock"],"stage":null,"founded_year":null,"location":"Australia","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/number-8-bio/","contact_email":null,"added_at":"2026-10-17T22:38:55.413Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-17T22:38:55.413Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"agtech","name":"AgTech","note":null,"profile_url":"/industries/agtech"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"climate-tech","name":"Climate Tech","note":null,"profile_url":"/industries/climate-tech"},{"kind":"industry","slug":"livestock","name":"Livestock","note":null,"profile_url":"/industries/livestock"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-17T22:38:55.413Z","updated_at":"2026-10-17T22:38:55.413Z"}},{"listing_type":"company","name":"insitro","slug":"insitro","tagline":"AI drug discovery company combining machine learning with large-scale human and cellular data to find new medicines","description":"insitro is a South San Francisco-based drug discovery company founded and led by AI pioneer Daphne Koller. Since 2018 it has built a large integrated multi-modal corpus of human and cellular data, the Virtual Human AI engine that models how disease begins and progresses, and the TherML platform that designs medicines against the causal drivers it identifies. insitro has partnered with large biopharma companies including Gilead (2019) and Bristol Myers Squibb (2020). On October 15, 2026 it announced a worldwide exclusive research collaboration with AstraZeneca to discover novel targets and therapeutics in MASH and cardiomyopathies, with $40 million upfront and up to approximately $1.46 billion in potential milestones plus royalties.","url":"https://www.insitro.com/","is_stealth":false,"normalized_domain":"insitro.com","normalized_url_key":"insitro.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.insitro.com/wp-content/uploads/2023/12/logo-insitro.png","links":[{"label":"X / Twitter","url":"https://x.com/insitro","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/insitro/","platform":"linkedin"},{"label":"insitro: AstraZeneca collaboration (Oct 15, 2026)","url":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","platform":"other"},{"label":"AstraZeneca press release (Oct 15, 2026)","url":"https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-new-strategic-collaboration-with-insitro-for-difficult-to-treat-cardiometabolic-diseases.html","platform":"other"},{"label":"Fierce Biotech: AstraZeneca inks $1.5B insitro deal","url":"https://www.fiercebiotech.com/biotech/astrazeneca-inks-15b-insitro-deal-ai-enabled-target-discovery","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://www.insitro.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"careers","url":"https://www.insitro.com/join-us/","audience":"human","label":"Careers","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://www.insitro.com/pipeline/","audience":"human","label":"Pipeline","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://www.insitro.com/platform/","audience":"human","label":"Platform","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.insitro.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Daphne Koller","role":"Founder and CEO","person_slug":"daphne-koller-2otnpmi9uxc7m","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"c2f171de-5fa1-4c40-a8bd-cad84650fb25"},"categories":["AI Drug Discovery","Biotech","Machine Learning","Therapeutics"],"stage":null,"founded_year":2018,"location":"South San Francisco, California, USA","pricing":null,"twitter":"https://x.com/insitro","github":null,"linkedin":"https://www.linkedin.com/company/insitro/","contact_email":null,"added_at":"2026-10-17T13:23:40.298Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-17T13:23:40.298Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-drug-discovery","name":"AI Drug Discovery","note":null,"profile_url":"/industries/ai-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"machine-learning","name":"Machine Learning","note":null,"profile_url":"/industries/machine-learning"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-17T13:23:40.298Z","updated_at":"2026-10-17T13:23:40.298Z"}},{"listing_type":"company","name":"Microbiotica","slug":"microbiotica","tagline":"Clinical-stage precision microbiome medicines for ulcerative colitis and cancer","description":"Microbiotica is a clinical-stage biopharma company near Cambridge, UK, spun out of the Wellcome Sanger Institute in 2016, developing orally dosed live biotherapeutic products. Its genomics-driven platform combines a gut microbiome culture collection, a proprietary reference genome database, bioinformatics and machine learning to identify bacteria associated with favourable clinical trial outcomes. Lead programme MB310, an eight-strain once-daily oral therapy for ulcerative colitis, met its Phase 1b endpoints, and MB097 is being developed with KEYTRUDA for advanced melanoma. On 16 October 2026 Microbiotica announced a £36 million ($48 million) Series C first close led by British Business Bank with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners to take MB310 into Phase 2.","url":"https://microbiotica.com/","is_stealth":false,"normalized_domain":"microbiotica.com","normalized_url_key":"microbiotica.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Favicon_RGB.png","links":[{"label":"X / Twitter","url":"https://x.com/MicrobioticaLtd","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/microbiotica-limited/","platform":"linkedin"},{"label":"Series C press release","url":"https://microbiotica.com/microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://microbiotica.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"blog","url":"https://microbiotica.com/press-releases/","audience":"human","label":"Press releases","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"careers","url":"https://microbiotica.com/working-here/","audience":"human","label":"Working here","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://microbiotica.com/pipeline/","audience":"human","label":"Pipeline","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://microbiotica.com/platform/","audience":"human","label":"Platform","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://microbiotica.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"c773eb05-0d47-4a1e-b2ed-7e27bef55b56"},"categories":["Biotech","Microbiome","Drug Development","Healthcare"],"stage":"series-b+","founded_year":null,"location":"Cambridge, United Kingdom","pricing":null,"twitter":"https://x.com/MicrobioticaLtd","github":null,"linkedin":"https://www.linkedin.com/company/microbiotica-limited/","contact_email":null,"added_at":"2026-10-16T22:40:16.996Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T22:40:16.996Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"microbiome","name":"Microbiome","note":null,"profile_url":"/industries/microbiome"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T22:40:16.996Z","updated_at":"2026-10-16T22:40:16.996Z"}},{"listing_type":"company","name":"Estuary Biotherapeutics","slug":"estuary-biotherapeutics","tagline":"Kidney-targeted AAV gene therapies for polycystic kidney disease (ADPKD)","description":"Estuary Biotherapeutics is a biotechnology company based in Newton, Massachusetts and Menlo Park, California, developing genetic medicines for serious kidney diseases, starting with autosomal dominant polycystic kidney disease (ADPKD). Its AAV gene therapies aim to add back a healthy copy of the PKD2 gene (EST-201) or a functional region of the PKD1 gene (EST-101), delivered locally to kidney cells. The company was co-founded by CEO Wayne Sackett with Yale scientific co-founders Stefan Somlo and Michael Caplan. On 16 October 2026 it launched with $103 million in total financing: a $93 million Series A led by RA Capital Management and a $10 million seed co-led by 4BIO Capital and GV. EST-201 is expected to enter clinical trials in 2027 and EST-101 in 2028.","url":"https://estuarybio.com/","is_stealth":false,"normalized_domain":"estuarybio.com","normalized_url_key":"estuarybio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://estuarybio.com/apple-icon.png","links":[{"label":"X / Twitter","url":"https://x.com/EstuaryBio","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/estuarybio","platform":"linkedin"},{"label":"Press release: $103M launch","url":"https://estuarybio.com/news/estuary-series-a","platform":"other"},{"label":"Yale Ventures: spinout announcement","url":"https://ventures.yale.edu/news/yale-spinout-estuary-biotherapeutics-launches-103-million-develop-gene-therapies-polycystic","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://estuarybio.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"blog","url":"https://estuarybio.com/news/estuary-series-a","audience":"human","label":"Series A announcement","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"contact","url":"https://estuarybio.com/contact","audience":"human","label":"Contact","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://estuarybio.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Wayne Sackett","role":"Co-founder and CEO","person_slug":"wayne-sackett-2uf0dvs0z7bm9","bio":null,"location":null,"links":[]},{"name":"Stefan Somlo","role":"Scientific co-founder","person_slug":"stefan-somlo-06hy94wqstsqd","bio":null,"location":null,"links":[]},{"name":"Michael Caplan","role":"Scientific co-founder","person_slug":"michael-caplan-1pe3j305nbrzm","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"1bdf94d1-a651-4a8e-be13-e6d12937cf74"},"categories":["Biotech","Gene Therapy","Healthcare","Kidney Disease"],"stage":"series-a","founded_year":null,"location":"Newton, Massachusetts, United States","pricing":null,"twitter":"https://x.com/EstuaryBio","github":null,"linkedin":"https://www.linkedin.com/company/estuarybio","contact_email":null,"added_at":"2026-10-16T22:24:45.262Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T22:24:45.262Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"kidney-disease","name":"Kidney Disease","note":null,"profile_url":"/industries/kidney-disease"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T22:24:45.262Z","updated_at":"2026-10-16T22:24:45.262Z"}},{"listing_type":"company","name":"HydRegen","slug":"hydregen","tagline":"Enzyme biocatalysts replacing precious-metal catalysts in chemical hydrogenation","description":"HydRegen is a University of Oxford spinout commercialising enzyme-based biocatalyst technology for hydrogenation reactions in pharmaceutical, specialty and bulk chemical manufacturing. Its slot-in products are designed to replace heavy-metal catalysts and fit existing batch or continuous-flow infrastructure. In October 2026 it announced an $8M (£6M) Series A first close led by Genoa Ventures, with Clean Growth Fund and First Imagine! Ventures participating.","url":"https://hydregenoxford.com/","is_stealth":false,"normalized_domain":"hydregenoxford.com","normalized_url_key":"hydregenoxford.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://images.squarespace-cdn.com/content/v1/604f0b51fdd7a73331edcddd/f52ef693-5537-4c4e-85c3-0076765cb346/HR_Master+logo.jpg?format=500w","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/20362048","platform":"linkedin"},{"label":"X / Twitter","url":"https://x.com/HydRegen_Oxford","platform":"x"},{"label":"YouTube","url":"https://www.youtube.com/channel/UCq9YqdQt4oLtXZ1Y94a7-uw","platform":"youtube"}],"entry_points":[{"kind":"homepage","url":"https://hydregenoxford.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"docs","url":"https://hydregenoxford.com/news","audience":"human","label":"News","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"docs","url":"https://hydregenoxford.com/technology","audience":"human","label":"Products","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://hydregenoxford.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"6f1f7c52-114f-437c-89db-4d0945886be2"},"categories":["Biotech","Industrial Biotechnology","Chemicals","Climate Tech"],"stage":"series-a","founded_year":null,"location":"Oxford, United Kingdom","pricing":null,"twitter":"https://x.com/HydRegen_Oxford","github":null,"linkedin":"https://www.linkedin.com/company/20362048","contact_email":null,"added_at":"2026-10-16T10:52:25.640Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T10:52:25.640Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"chemicals","name":"Chemicals","note":null,"profile_url":"/industries/chemicals"},{"kind":"industry","slug":"climate-tech","name":"Climate Tech","note":null,"profile_url":"/industries/climate-tech"},{"kind":"industry","slug":"industrial-biotechnology","name":"Industrial Biotechnology","note":null,"profile_url":"/industries/industrial-biotechnology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T10:52:25.640Z","updated_at":"2026-10-16T10:52:25.640Z"}},{"listing_type":"company","name":"OlsAro","slug":"olsaro","tagline":"Seed genetics platform for climate-resilient cereals","description":"OlsAro is a Swedish agtech company developing climate-resilient cereal traits and varieties with its SeedAX platform, which combines a proprietary seed population, genetics and AI-based trait discovery with field testing. Its salinity-tolerant wheat showed up to 41% higher yields in saline conditions over four years of trials in Bangladesh, and it is working on heat, drought and nitrogen-use efficiency traits. In October 2026 it closed a €5M seed round led by Industrifonden with Nordic Foodtech VC.","url":"https://olsaro.com/","is_stealth":false,"normalized_domain":"olsaro.com","normalized_url_key":"olsaro.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://olsaro.com/wp-content/uploads/2020/09/OlsAro_logo_Cmyk__no-tagline-01.png","links":[],"entry_points":[{"kind":"homepage","url":"https://olsaro.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"docs","url":"https://olsaro.com/products/","audience":"human","label":"Products","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"docs","url":"https://olsaro.com/technology/","audience":"human","label":"Technology","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://olsaro.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"e541e70f-4364-4e0b-b4d8-7d749d2e73ab"},"categories":["AgTech","Biotech","Climate Tech","Food Security"],"stage":"seed","founded_year":null,"location":"Sweden","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-16T10:37:36.489Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T10:37:36.489Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"agtech","name":"AgTech","note":null,"profile_url":"/industries/agtech"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"climate-tech","name":"Climate Tech","note":null,"profile_url":"/industries/climate-tech"},{"kind":"industry","slug":"food-security","name":"Food Security","note":null,"profile_url":"/industries/food-security"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T10:37:36.489Z","updated_at":"2026-10-16T10:37:36.489Z"}},{"listing_type":"company","name":"Acta Pharmaceuticals","slug":"acta-pharmaceuticals","tagline":"Alzheimer's therapies for early intervention and prevention, led by gamma-secretase modulator research","description":"Acta Pharmaceuticals, Inc. is a Boston biotech translating Alzheimer's research pioneered by scientific founder Dr. Rudolph E. Tanzi into clinical candidates for early intervention and prevention. Its lead program, GSM-779690T, is an oral gamma-secretase modulator in a Phase 1 healthy-volunteer study. In October 2026 the company announced closing $24 million in seed financing to advance the pipeline, alongside a combination-therapies discovery effort based on Alzheimer's-in-a-Dish models.","url":"https://actapharmaceuticals.com/","is_stealth":false,"normalized_domain":"actapharmaceuticals.com","normalized_url_key":"actapharmaceuticals.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://actapharmaceuticals.com/wp-content/uploads/2026/10/ACTA-Logo-26-FIN.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/acta-pharmaceuticals","platform":"linkedin"},{"label":"Funding announcement","url":"https://www.biospace.com/press-releases/acta-pharmaceuticals-closes-24-million-in-seed-financing-for-alzheimers-disease-pipeline-targeting-early-intervention-and-prevention"},{"label":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT07690228"}],"entry_points":[{"kind":"homepage","url":"https://actapharmaceuticals.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://actapharmaceuticals.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Rudolph E. Tanzi","role":"Scientific Founder","person_slug":"rudolph-e-tanzi-08macy2crbbz6","bio":null,"location":null,"links":[]},{"name":"George Alex","role":"Co-founder and CEO","person_slug":"george-alex-3gf4y8gl8xgyq","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"4b04d244-23da-4884-9262-5e34accafa91"},"categories":["Biotech","Healthcare","Pharmaceuticals","Alzheimer's"],"stage":"seed","founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/acta-pharmaceuticals","contact_email":null,"added_at":"2026-10-16T04:26:23.693Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T04:26:23.693Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"alzheimers","name":"Alzheimer's","note":null,"profile_url":"/industries/alzheimers"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","note":null,"profile_url":"/industries/pharmaceuticals"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T04:26:23.693Z","updated_at":"2026-10-16T04:26:23.693Z"}}],"total":265,"limit":50,"offset":0}